Imac holdings announces $4.3 million private placement of convertible preferred stock and warrants priced at the market

Franklin, tennessee, july 26, 2023 (globe newswire) -- imac holdings, inc. (nasdaq: back) (“imac” or the “company” ), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of theralink technologies, inc., its previously announced merger partner (otc:ther) (“theralink”), and theralink's chairman, for the sale of its preferred stock and warrants. imac sold an aggregate of 2,500 shares of its series a-1 convertible preferred stock, stated value $1,000 per share, 1,800 shares of its series a-2 convertible preferred stock, stated value $1,000 per share, and warrants to purchase up to 62,271,063 shares of its common stock for aggregate gross proceeds of $4,300,000 before deducting placement agent fees and other offering expenses. the shares of a-1 convertible preferred stock, shall bear a 12% dividend, and are initially convertible into an aggregate of 22,893,773 shares of common stock of the company, and the shares of series a-2 convertible preferred stock are initially convertible into an aggregate of 16,483,517 shares of common stock of the company, in each case, at a conversion price of $0.1092 per share. the warrants have an exercise price of $0.1092 per share, are exercisable immediately, and will expire five years from the date of shareholder approval of this private placement. it is expected that approximately $3.0 million of the proceeds of the offering will be used to make a loan to theralink for investment into sales and marketing efforts and general working capital purposes as the companies continue to take formal steps together in advancing their merger previously announced on may 23, 2023.
BACK Ratings Summary
BACK Quant Ranking